Tivozanib Publications & Presentations | AVEO Oncology

Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

January 24, 2022
PresentationTivozanib

ASCO GI 2022: A Phase 1b/2 Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma (DEDUCTIVE): Efficacy Results in Previously Untreated Patients

June 4, 2021
PresentationTivozanib

ASCO 2021: TIVO-3: Durability of Response and Updated Overall Survival of Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma (mRCC)

June 4, 2021
PresentationTivozanib

ASCO 2021: Temporal Characteristics of Treatment-Emergent Adverse Events and Dose Modifications With Tivozanib and Sorafenib in the Phase 3 TIVO-3 Study of Relapsed or Refractory mRCC

February 11, 2021
PresentationTivozanib

ASGO GU 2021: Q-TWiST analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study

February 11, 2021
PresentationTivozanib

ASCO GU 2021: Tivozanib in Patients with Advanced Renal Cell Carcinoma (aRCC) who have Progressed After Prior Treatment with Axitinib: Results from TIVO-3

January 15, 2021
PresentationTivozanib

ASCO GI 2021: DEDUCTIVE: a Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma; Phase Ib results

1 2 3 4 5 6 … 12

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.